MERS-CoV S Specific Neutra™ Antibody Products

Are you currently facing challenges in developing sensitive neutralization assays, struggling with cross-reactivity issues, or encountering low-affinity binders in your MERS-CoV research? Creative Biolabs' MERS-CoV S specific Neutra™ antibody products help you obtain high-quality recombinant antibodies and develop robust therapeutic candidates through our advanced protein engineering technology and high-throughput screening platform.

Introduction to MERS-CoV S

The Middle East Respiratory Syndrome Coronavirus Spike (MERS-CoV S) Glycoprotein is the primary determinant of viral entry and the principal target for neutralizing antibody development. As the key surface structure, MERS-CoV S dictates host tropism and pathogenicity.

• Basic Characteristics

MERS-CoV S is a large, type I transmembrane glycoprotein found on the surface of the virus, giving it the characteristic corona appearance. Unlike SARS-CoV and SARS-CoV-2, which utilize the ACE2 receptor, MERS-CoV S specifically binds to dipeptidyl peptidase 4 (DPP4/CD26) to gain entry into host cells. This unique receptor specificity is a critical factor in the virus's pathology and is the focal point for immunological intervention.

Fig.1 Schematic structures of MERS-CoV proteins.^1,3

• Structure

The MERS-CoV S protein exists as a metastable homotrimer. It is synthesized as a precursor that is proteolytically cleaved by host furin-like proteases into two distinct functional subunits: S1 and S2. The S1 subunit contains the receptor-binding domain (RBD), which is responsible for the specific high-affinity interaction with the host DPP4 receptor. The S2 subunit comprises the fusion machinery, containing the fusion peptide and heptad repeats necessary for merging viral and cellular membranes.

• Function

The primary function of MERS-COV S is to mediate viral entry. This process is initiated by the binding of the S1-RBD to DPP4 on the surface of respiratory or renal epithelial cells. Following receptor attachment, a second proteolytic cleavage event exposes the fusion peptide within the S2 subunit. This triggers a dramatic structural rearrangement, transitioning the protein from a pre-fusion to a post-fusion state, thereby facilitating the fusion of the viral envelope with the host cell membrane and releasing the viral RNA genome into the cytoplasm.

Fig.2 Proposed mechanism of membrane fusion promoted by MERS-CoV S.^2,3

• Related Signaling Pathways
  Infection mediated by MERS-CoV S perturbs critical host cell signaling networks to facilitate viral survival and pathogenesis:
  • Interferon (IFN) Antagonism: The virus actively suppresses the induction of Type I and Type III interferons, dismantling the host's initial innate antiviral defense and allowing for rapid viral replication.
  • Apoptotic Signaling: Interaction with the DPP4 receptor and subsequent viral replication stress triggers both intrinsic (mitochondrial) and extrinsic death receptor pathways, leading to programmed cell death in renal and respiratory epithelial cells.
  • Pro-inflammatory Cascades: The infection dysregulates cytokine production, often stimulating excessive inflammatory signaling (e.g., p38 MAPK or NF-κB activation), which contributes to the "cytokine storm" and severe tissue injury associated with MERS.
• Related Diseases

MERS-CoV S is the causative agent of MERS. This disease manifests as a spectrum of respiratory illnesses ranging from asymptomatic cases to severe acute respiratory distress syndrome (ARDS), septic shock, and multi-organ failure. A distinguishing feature of MERS, compared to other human coronaviruses, is the high prevalence of acute renal failure, correlated with the expression of DPP4 in kidney tissue.

Applications of MERS-CoV S Neutralizing Antibodies

• Therapeutic Monoclonal Antibody Development

Neutralizing antibodies targeting MERS-CoV S are the most promising candidates for therapeutic intervention. By binding specifically to the RBD of the S1 subunit, these antibodies sterically hinder the interaction between the virus and the DPP4 receptor. This blockade effectively prevents viral attachment and entry, reducing viral load and mitigating disease severity in infected patients.

• Prophylactic Passive Immunotherapy

Anti-MERS-CoV S antibodies serve a critical role in prophylaxis, particularly for healthcare workers and individuals with comorbidities during outbreak scenarios. Administering high-affinity neutralizing antibodies prior to exposure can provide immediate passive immunity, preventing infection establishment and curbing nosocomial transmission chains in hospital settings.

• Vaccine Efficacy Evaluation

In vaccine development, MERS-CoV S neutralizing antibodies are indispensable tools for immunogenicity assessment. They are used as positive controls and standards in assays to quantify the humoral immune response generated by candidate vaccines. Measuring the titer of S-specific neutralizing antibodies in serum is a primary correlate of protection in preclinical and clinical trials.

• Diagnostic Assay Development

Specific antibodies against MERS-CoV S are utilized to develop rapid and sensitive diagnostic kits, including ELISA and lateral flow immunoassays. These tools detect the presence of viral antigens in patient samples, facilitating early diagnosis and isolation. High-specificity antibodies are crucial for distinguishing MERS-CoV from other circulating betacoronaviruses to prevent false positives.

• Structural Biology and Epitope Mapping

Researchers employ these antibodies in structural biology studies, such as Cryo-EM and X-ray crystallography, to stabilize the S protein in specific conformations. This application allows for the precise mapping of antigenic epitopes and the identification of conserved vulnerability sites on the spike protein, guiding rational design for next-generation broad-spectrum therapeutics.

• Pseudovirus Neutralization Assays

To study viral entry mechanisms safely in lower biosafety level laboratories (BSL-2), researchers utilize anti-MERS-CoV S antibodies in pseudovirus neutralization assays. These antibodies validate the specificity of the pseudotyped particles and are used to screen small molecule inhibitors or peptide blockers that disrupt the S-protein mediated fusion process.

Our Anti-MERS-CoV S Antibodies

Creative Biolabs offers a premium portfolio of Anti-MERS-CoV S antibodies, engineered to support the rigorous demands of virology research and therapeutic discovery. Our catalog features a diverse range of monoclonal and recombinant antibodies validated for high specificity and potent neutralizing activity.

• Diverse Host Options: We provide antibodies derived from various hosts, including mouse and humanized versions, to suit different detection systems and reduce background noise in cross-species assays.
• High-Affinity Recombinant Antibodies: Our recombinant antibody technology ensures batch-to-batch consistency and superior affinity, essential for reproducible results in sensitive neutralization assays.
• Broad Application Compatibility: These antibodies are rigorously tested and optimized for use in multiple applications, including ELISA, Western Blotting, Flow Cytometry, and functional Neutralization tests.
• Target Specificity: We offer antibodies that target distinct epitopes on the S1 RBD, S2 subunit, and the full-length Spike protein, allowing for precise dissection of viral entry mechanisms and fusion steps.
• Chimeric and Human IgG Formats: To facilitate therapeutic development, we offer Chimeric and fully Human IgG formats ideal for preclinical efficacy studies and safety profiling.

Creative Biolabs is dedicated to accelerating your infectious disease research with our high-purity, validated MERS-CoV S specific Neutra™ antibody products. We empower your laboratory to achieve breakthroughs in therapeutics and diagnostics with confidence. Contact our team to learn more and discuss your project.

References

1. Rabaan, Ali A., et al. "MERS-CoV: epidemiology, molecular dynamics, therapeutics, and future challenges." Annals of Clinical Microbiology and Antimicrobials 20.1 (2021): 8. https://doi.org/10.1186/s12941-020-00414-7
2. Yuan, Yuan, et al. "Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains." Nature Communications 8.1 (2017): 15092. https://doi.org/10.1038/ncomms15092IF:
3. Distributed under Open Access license CC BY 4.0, without modification.